$\square$ 

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person* <u>Forbion Capital Fund II Cooperatief U.A.</u>			2. Issuer Name and Ticker or Trading Symbol HOOKIPA Pharma Inc. [HOOK]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner
(Last) C/O HOOKIPA I 350 FIFTH AVE	(First) PHARMA INC. NUE, 72ND FLOC	(Middle) DR. SUITE 7240	3. Date of Earliest Transaction (Month/Day/Year) 04/23/2019	. Officer (give title Other (specify below) below)
(Street) NEW YORK NY 10118 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 Non Derivative Occurries Adquired, Disposed of, of Derivitiany owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)	
Common Stock	04/23/2019		С		687,673	Α	(1)	696,987	Ι	See Footnote <sup>(2)</sup>	
Common Stock	04/23/2019		С		1,146,118	A	(1)	1,843,105	Ι	See Footnote <sup>(2)</sup>	
Common Stock	04/23/2019		С		597,497	A	(1)	2,440,602	Ι	See Footnote <sup>(2)</sup>	
Common Stock	04/23/2019		Р		53,571	A	\$14	2,494,173	Ι	See Footnote <sup>(2)</sup>	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Preferred Stock	(1)	04/23/2019		С			687,673	(1)	(1)	Common Stock	687,673	(1)	0	I	See Footnote <sup>(2)</sup>
Series B Preferred Stock	(1)	04/23/2019		С			1,146,118	(1)	(1)	Common Stock	1,146,118	(1)	0	I	See Footnote <sup>(2)</sup>
Series C Preferred Stock	(1)	04/23/2019		С			597,497	(1)	(1)	Common Stock	597,497	(1)	0	I	See Footnote <sup>(2)</sup>

Explanation of Responses:

1. The preferred stock automatically converted into the Issuer's common stock on a one-for-one basis at the closing of the Issuer's initial public offering held on April 23, 2019 without payment or further consideration and had no expiration date.

2. Represents securities held by Forbion Capital Fund II Cooperatief U.A. ("Forbion Coop:"). Forbion II Management B.V. ("Forbion Management") is the director of Forbion Coop and may be deemed to have voting, investment and dispositive power with respect to the shares held by Forbion Coop. Forbion Management disclaims Section 16 beneficial ownership of the shares held by Forbion Coop, except to the extent, if any, of its pecuniary interest therein.

 Forbion II Management B.V.,

 director of Forbion Capital Fund

 II Cooperatief U.A., By: /s/
 04/25/2019

 Sander Slootweg and V. Van

 Houten as directors

 \*\* Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.